SYNERGISTIC EFFECT OF GANCICLOVIR AND FOSCARNET ON CYTOMEGALOVIRUS REPLICATION INVITRO

被引：109

作者：

MANISCHEWITZ, JF ^{[1
]}

QUINNAN, GV ^{[1
]}

LANE, HC ^{[1
]}

WITTEK, AE ^{[1
]}

机构：

[1] NIAID,CLIN IMMUNOL LAB,BETHESDA,MD 20892

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1990年 / 34卷 / 02期

关键词：

D O I：

10.1128/AAC.34.2.373

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ganciclovir and foscarnet possess substantial activity against cytomegalovirus. Both exhibit dose-limiting toxicity, which reduces their clinical usefulness. We demonstrated synergistic inhibition of cytomegalovirus replication in vitro by ganciclovir and foscarnet. Reduced-dose combination therapy may provide a means to treat patients with cytomegalovirus infection while reducing drug toxicity.

引用

页码：373 / 375

页数：3

共 50 条

[31] FOSCARNET-GANCICLOVIR CYTOMEGALOVIRUS RETINITIS TRIAL .4. VISUAL OUTCOMES
JABS, DA
OPHTHALMOLOGY, 1994, 101 (07) : 1250 - 1261
[32] COMBINATION THERAPY WITH FOSCARNET AND GANCICLOVIR FOR CLINICALLY RESISTANT CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
WEINBERG, DV
MURPHY, RL
HIRSCHTICK, RE
SCURRY, J
NAUGHTON, K
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 1108 - 1108
[33] Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis
Fan, Jing-Jing
Tao, Yong
Hwang, De-Kuang
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2018, 11 (10) : 1638 - 1642
[34] Foscarnet-ganciclovir cytomegalovirus retinitis trial .5. Clinical features of cytomegalovirus retinitis at diagnosis
Lewis, RA
Clogston, P
Fainstein, V
Gross, R
Samo, T
Tuttle, C
Jabs, DA
Apuzzo, L
Bartlett, J
Coleson, L
Dunn, JP
Eldred, L
Feinberg, J
Flynn, T
King, R
Leslie, J
Barron, B
Greenspan, D
LeCount, C
Peyman, G
Franklin, R
Heinemann, MH
Polsky, B
Squires, K
WiseCampbell, S
Friedman, AH
Cheung, TW
Justin, N
Teich, S
Sacks, H
Severin, C
Friedberg, DN
Addessi, A
Dieterich, D
Frost, K
Weinberg, D
Jampol, L
Murphy, R
Naughton, K
Henderly, D
Holland, GN
Chafey, S
Fall, H
Hardy, WD
Kimbrell, C
MacArthurChang, L
Freeman, WR
Meixnert, L
Peterson, TJ
Quiceno, JI
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (02) : 141 - 157
[35] INCREASED EFFICACY OF GANCICLOVIR IN COMBINATION WITH FOSCARNET AGAINST CYTOMEGALOVIRUS AND HERPES-SIMPLEX VIRUS TYPE-2 INVITRO AND INVIVO
FREITAS, VR
FRASERSMITH, EB
MATTHEWS, TR
ANTIVIRAL RESEARCH, 1989, 12 (04) : 205 - 212
[36] Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis
Jing-Jing Fan
Yong Tao
De-Kuang Hwang
International Journal of Ophthalmology, 2018, 11 (10) : 1638 - 1642
[37] CONCURRENT USE OF GANCICLOVIR AND FOSCARNET TO TREAT CYTOMEGALOVIRUS-INFECTION IN AIDS PATIENTS
DIETERICH, DT
POLES, MA
LEW, EA
MENDEZ, PE
MURPHY, R
ADDESSI, A
HOLBROOK, JT
NAUGHTON, K
FRIEDBERG, DN
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05): : 1184 - 1188
[38] Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections
Jacobson, MA
ANTIVIRAL CHEMOTHERAPY 4: NEW DIRECTIONS FOR CLINICAL APPLICATION AND RESEARCH, 1996, 394 : 85 - 92
[39] Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
C Ippoliti
A Morgan
D Warkentin
K van Besien
R Mehra
I Khouri
S Giralt
J Gajewski
R Champlin
B Andersson
D Przepiorka
Bone Marrow Transplantation, 1997, 20 : 491 - 495
[40] PROLONGED CONCURRENT USE OF GANCICLOVIR AND FOSCARNET IN THE TREATMENT OF POLYRADICULOPATHY DUE TO CYTOMEGALOVIRUS IN A PATIENT WITH AIDS
DECKER, CF
TARVER, JH
MURRAY, DF
MARTIN, GJ
CLINICAL INFECTIOUS DISEASES, 1994, 19 (03) : 548 - 549

← 1 2 3 4 5 →